| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 08/23/2005 | CA2172508C Method for preparing microspheres comprising a fluidized bed drying step |
| 08/23/2005 | CA2142300C Methods for detecting alzheimer's disease |
| 08/23/2005 | CA2094464C Mutant respiratory syncytial virus (rsv) vaccines containing same and methods of use |
| 08/23/2005 | CA2094276C Antibodies against the urokinase receptor and their use |
| 08/23/2005 | CA2070281C Improved treatment of autoimmune diseases by aerosol administration of auto antigens |
| 08/18/2005 | WO2005076003A2 Diagnostics and therapeutics for diseases associated with plasma glutamate carboxypeptidase (pgcp) |
| 08/18/2005 | WO2005075679A2 Antigenic hiv-1 peptides |
| 08/18/2005 | WO2005075666A2 Diagnostics and therapeutics for diseases associated with puromycin sensitive aminopeptidase npepps (npepps) |
| 08/18/2005 | WO2005075665A2 Diagnostics and therapeutics for diseases associated with plasma kallikrein (klkb1) |
| 08/18/2005 | WO2005075653A1 Cell surface expression vector of parvovirus antigen and microorganisms transformed thereof |
| 08/18/2005 | WO2005075647A1 Humanized antibody |
| 08/18/2005 | WO2005075646A1 Peptide originating in stress-induced antiapoptosis molecule (iex-1) |
| 08/18/2005 | WO2005075504A1 IDENTIFICATION OF NOVEL IgE EPITOPES |
| 08/18/2005 | WO2005075003A1 Implantable medical devices for treating or preventing restenosis |
| 08/18/2005 | WO2005074986A2 Bioactive species capable of interfering with a microbial toxin-antitoxin complex and methods for evaluation and use of said bioactive species |
| 08/18/2005 | WO2005074984A1 Hmgb1 protein inhibitors for the regulation of smooth muscle cells and endothelial cells profileration |
| 08/18/2005 | WO2005074983A2 Treatment of rhinitis with anticholinergics alone in combination with antihistamines phosphodiesterase 4 inhibitors, or corticosteroids |
| 08/18/2005 | WO2005074980A1 Treatment of neurodegenerative diseases by the use of gpr49 |
| 08/18/2005 | WO2005074973A2 Method of inducing or modulating immune response |
| 08/18/2005 | WO2005074971A1 Treatment of neurodegenerative diseases by the use of cgi-13 interacting molecules |
| 08/18/2005 | WO2005074645A2 Methods and compositions for modulating angiogenesis |
| 08/18/2005 | WO2005074633A2 Compositions and methods for characterizing, regulating, diagnosing, and treating cancer |
| 08/18/2005 | WO2005074607A2 Method of treating hemolytic disease |
| 08/18/2005 | WO2005074572A2 Methods and compositions for detecting of equine tapeworm infections |
| 08/18/2005 | WO2005074460A2 Methods of enhancing immune response in the intradermal compartment and compounds useful in the methods |
| 08/18/2005 | WO2005052122A3 METHODS FOR CONTROLLING PATHOLOGICAL ANGIOGENESIS BY INHIBITION OF α6β4 INTEGRIN |
| 08/18/2005 | WO2005039632B1 Colorectal cancer antigen |
| 08/18/2005 | WO2005033133A3 Polynucleotides encoding erbb-2 polypeptides and kits and methods using same |
| 08/18/2005 | WO2005032572A3 Means and methods for the recruitment and identification of stem cells |
| 08/18/2005 | WO2005027846A3 Elicitation of antibodies to self peptides in mice by immunization with dendritic cells |
| 08/18/2005 | WO2005027841A3 Cells, compositions and methods for repressing b cell autoantibody secretion and for treating autoimmune disease |
| 08/18/2005 | WO2005026318A3 Methods and compositions for producing antigenic responses |
| 08/18/2005 | WO2005023830A3 Ozonation products of cholesterol for the treatment and prevention of atherosclerosis and/or cardiovascular diseases |
| 08/18/2005 | WO2005013899A3 Compositions and methods for the therapy and diagnosis of lung cancer |
| 08/18/2005 | WO2005007868A3 Controlled platelet activation to monitor therapy of adp antagonists |
| 08/18/2005 | WO2005007691A3 East coast fever vaccine based on ctl-specific schizont antigens |
| 08/18/2005 | WO2005001096A8 Vaccines against sars |
| 08/18/2005 | WO2004100898A3 Therapeutic use of anti-cs1 antibodies |
| 08/18/2005 | WO2004098636A8 Vaccinating against infectious diseases using proteosomes |
| 08/18/2005 | WO2004094607A3 Methods of therapy and diagnosis using targeting of cells that express a human transporter-like protein |
| 08/18/2005 | WO2004066946A3 Method for evaluating the efficacy of certain cancer treatments |
| 08/18/2005 | WO2004054516A3 Antagonists for human prolactin |
| 08/18/2005 | WO2004020463A3 Mutant protein and refolding method |
| 08/18/2005 | WO2003072601A8 Method for producing hypoallergenic major birch pollen allergens rbet v 1 |
| 08/18/2005 | WO2003004608A3 Drug metabolizing enzymes |
| 08/18/2005 | WO2002099049A3 Tbc1d1s as modifiers of the p53 pathway and methods of use |
| 08/18/2005 | US20050182249 Nucleotide sequences coding tumor suppressor protein for use in diagnosis, prevention and treatment of cancer; antitumor agents |
| 08/18/2005 | US20050182244 Modified polypeptides stabilized in a desired conformation and methods for producing same |
| 08/18/2005 | US20050182017 Immunostimulatory nucleic acid molecules |
| 08/18/2005 | US20050182011 Use inhibitors of Transient Receptor Potential (TRP) channels to block non-voltage gated calcium flux into cells |
| 08/18/2005 | US20050182003 Drugs to be used in gene therapy for recessively transmitted genetic disease |
| 08/18/2005 | US20050181985 Coupling proteins to a modified polysaccharide |
| 08/18/2005 | US20050181507 Gene delivery vectors with cell type specificity for mesenchymal stem cells |
| 08/18/2005 | US20050181501 Anti-TECK antibodies and methods of use therefor |
| 08/18/2005 | US20050181482 Immunoglobulin/erythropoietin fusion for use in stimulating blood cell production |
| 08/18/2005 | US20050181475 Immunoglobulin which comprises at least two different epitopes of a tumor-associated antigen for use as diagnostic and therapeutic tool in detection, treatment and prevention of cell proliferative disorders; immunotherapy |
| 08/18/2005 | US20050181457 Mixture comprising immunogllobulin G complex for diagnosis, prevention and treatment of autoimmune and allergic disorders |
| 08/18/2005 | US20050181448 Biological products |
| 08/18/2005 | US20050181439 Streptococcus pneumoniae antigens and vaccines |
| 08/18/2005 | US20050181419 For detection of Mycobacterium tuberculosis infection |
| 08/18/2005 | US20050181413 Ovarian specific nucleic acid (OSNA) for use as diagnostic and prognostic tools in treatment and prevention of urogenital cancers; genetic vaccines |
| 08/18/2005 | US20050181402 Immunoglobulin which specifically binds serum and glucocorticoid dependent kinase for diagnosing infection, inflammatory, kidney and liver disorders |
| 08/18/2005 | US20050181358 Soluble complex comprising a retroviral surface glycoprotein |
| 08/18/2005 | US20050181064 Drugs comprising protein forming hollow nanoparticles and therapeutic substance to be transferred into cells fused therewith |
| 08/18/2005 | US20050181063 Biologically active agent being encapsulated within microspheres which comprise a polymer which has a molecular weight in excess of 94 kDa and a maximum diameter of 20 mu m; for the intra-nasal administration of vaccines in a single shot vaccination |
| 08/18/2005 | US20050180996 Vaccine composition specific to glyceroaldehyde-3-phosphate dehydrogenase for use as tool in prevention and treatment of coccidiosis; veterinary medicine |
| 08/18/2005 | US20050180994 or drug targets; determining a candidate's effect on ubiquitin ligase activity of the poxviral p28 polypeptide; ubiquitylating a substrate by combining an E1 polypeptide, an E2 polypeptide, ubiquitin and a poxvirus P28 protein; variola virus (smallpox) treatment; side effect reduction of vaccination |
| 08/18/2005 | US20050180993 Assays for the identification of compounds that inhibit assembly of nucleoprotein (NP), virion-associated proteins VP35, and VP24, or inhibit the glycosylation of NP, required for nucleocapsid formation, for use as anti-viral agents |
| 08/18/2005 | US20050180992 Fabricating wet spun or electrospun fibers using nanometer scale liquid crystalline viral particle suspensions where particle composition and function can be modified genetically to include binding or nucleating conjugate moieties while maintaining fibrous structure end product |
| 08/18/2005 | US20050180987 Method of separating protective components of bordetella pertussis |
| 08/18/2005 | US20050180986 Collagen-binding proteins from Enterococcal bacteria |
| 08/18/2005 | US20050180985 Live attenuated salmonella strains for producing monovalent or multivalent vaccines |
| 08/18/2005 | US20050180984 Modulating vaccine against HIV-1 Nef protein induced lymphocyte depletion |
| 08/18/2005 | US20050180983 Antibody vaccine conjugates and uses therefor |
| 08/18/2005 | US20050180982 Assessing metastatic potential of carcinoma cells by contacting cells in tissue sample suspected of containing carcinoma with detectable indicator capable of binding to cad-11 or cad-11 mRNA and determining presence or absence of cad-11 expression in tissue; method of preventing or terminating pregnancy |
| 08/18/2005 | US20050180978 Isolated monoclonal antibody mAb PAB-1, deposited at ATCC on 24 Jan. 2002 and accorded accession PTA-4005, which binds to a surface antigen on nematode L3; use in preventing or treating animal nematode infections |
| 08/18/2005 | US20050180977 Antibodies that bind to ET2, such as immunoglobulins that inhibit ET2 with high affinity and selectivity; can be used to treat angiogenesis-associated disorders. |
| 08/18/2005 | US20050180975 Combined use of anti-cytokine antibodies or antagonists and anti-CD20 for treatment of B cell lymphoma |
| 08/18/2005 | US20050180974 directly delivering interleukin 10 signal transduction modifying agent to cerebrospinal fluid and/or brain tissue |
| 08/18/2005 | US20050180973 TREM-1 splice variant for use in modifying immune responses |
| 08/18/2005 | US20050180972 high potency and/or are capable of promoting accumulation of the anti-CD20 ADC into CD20-expressing cells; pharmaceutical compositions and kits |
| 08/18/2005 | US20050180971 Cancer therapy |
| 08/18/2005 | US20050180969 which binds to B lymphoblastoid cells and induces proliferation and activation of peripheral blood lymphocytes; anti-tumor effect when injected into a tumor-bearing subject |
| 08/18/2005 | US20050180968 RLX is able to modulate the biological activity of bone marrow-derived cells, such as mast cells, platelets and granulocytes, and to reduce the allergic asthma-like reaction elicited by antigen inhalation |
| 08/18/2005 | US20050180963 Probiotic propionibacterium |
| 08/18/2005 | US20050180960 producer cell (encapsulated in a matrix containing immunostimulating alginates) expresses a molecule that is an inhibitor of the growth of a CNS tumor |
| 08/18/2005 | US20050180959 Kinases involved in the regulation of energy homeostasis |
| 08/18/2005 | US20050180952 agent has a higher tissue bioavailability in a particular tissue; benefits and improvements over conventional drug delivery methods including dose sparing, increased drug efficacy, reduced side effects, reduced metastatic potential and prolonged survival |
| 08/18/2005 | US20050180951 Fusion of autologous dendrtic cells with cancer cells that have the same class I MHC haplotype as said patient; and interleukin-12 |
| 08/18/2005 | US20050180950 Chemically modified TNF-alpha |
| 08/18/2005 | US20050180947 Novel application of vaccination against TNF-alpha |
| 08/18/2005 | EP1572729A3 Mutant protein and refolding method |
| 08/18/2005 | DE102004004787A1 New effector-linker and effector-recognition unit conjugates derived from epothilones, useful as targeted drugs for treating proliferative diseases, e.g. tumors or neurodegenerative disease |
| 08/18/2005 | DE102004003572A1 Monoparamunitätsinducer basierend auf attenuierten Myxomaviren des Kaninchens Monoparamunity based on attenuated rabbit myxomaviruses |
| 08/18/2005 | CA2560055A1 Method of inducing or modulating immune response |
| 08/18/2005 | CA2555306A1 Humanized antibody |
| 08/18/2005 | CA2554880A1 Methods and compositions for modulating angiogenesis |
| 08/18/2005 | CA2554779A1 Compositions and methods for characterizing, regulating, diagnosing, and treating cancer |
| 08/18/2005 | CA2554632A1 Method of treating hemolytic disease |
| 08/18/2005 | CA2554628A1 Methods of modulating cd200 and cd200r |